Crossmark

Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?

Crossref DOI link: https://doi.org/10.1016/j.reumae.2023.11.002

Published Print: 2024-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Albayrak, Fatih

Gür, Mustafa

Karataş, Ahmet

Koca, Süleyman Serdar

Kısacık, Bünyamin
License Information

Text and Data Mining valid from 2024-03-01
More Information

This article is maintained by: Elsevier

Article Title: Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2023.11.002

Content Type: article

Copyright: © 2023 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.